TMAN Targets 4 Billion Baht Revenue in 3 Years, Pushes into Longevity and Drives Propoliz Toward Regional Brand Status

T. Man Pharmaceutical Public Company Limited, or TMAN, has announced it is building a New S-Curve in the Health & Wellness business group through Longevity innovation via the Heaven Herb factory, one of the group's most fully integrated production bases. Chief Executive Officer Praphon Thanachotiphan revealed that the five-year business plan will deliver approximately 15 Science-backed Longevity Solutions products (SKUs), covering metabolic and cellular systems, gut health and inflammation, brain and sleep, as well as skin health. Over the next 3-5 years, the company aims to generate 5-10% of its portfolio revenue from this group, making it a new Growth Engine for the organisation. The company estimates Thailand's Healthcare market value in 2026 at approximately 37.65 billion US dollars, and expects it to rise to approximately 61.38 billion US dollars in 2033, growing at an average of 8.49% per year. Chief Operating Officer Tras Absuwan said the Heaven Herb factory operates on a fully integrated basis, from extracting active substances from herbs to developing and processing them into herbal products, dietary supplements and cosmetics under GMP PIC/S, ISO 22716 and ISO 22000 standards, with a plan to fully transform into a Smart Factory and to operate under an ESG framework. It has received Level 2 Green Industry certification and a Level 3 White Factory award.

The Animal Longevity Summit has announced its inaugural two-day scientific conference, taking place October 1–2, 2026, in Toronto. The event will bring together leading experts in geroscience, veterinary medicine, biotechnology, and aging research to explore how the biology of aging can be measured, slowed, and translated into longer, healthier lives, beginning with animals. The summit arrives as landmark initiatives such as the Dog Aging Project and a growing number of veterinary clinical trials generate the first large-scale datasets on interventions to improve healthspan and longevity in companion animals. The conference program will feature eight scientific tracks covering canine longevity, comparative biology of aging, biomarkers, longevity interventions, veterinary geroscience, cross-species translation to human health, and emerging research from early-career scientists. The inaugural speaker lineup includes Dr. Matt Kaeberlein of the Dog Aging Project, Dr. Vera Gorbunova of the University of Rochester, Dr. Aubrey de Grey of the LEV Foundation, Dr. Varun Dwaraka of TruDiagnostic, Liz Parrish of BioViva, and Dr. Raghav Sehgal of Yale, with additional speakers to be announced. Industry participation is also expected, with Genflow Biosciences confirming it will present new findings from its SLAB study investigating gene therapy in aged beagles.